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EuroAlliance (a consortium of Alfa Wassermann SpA, Lacer SA 
and Merckle GmbH) is developing licofelone, a dual 
cyclooxygenase and 5-lipoxygenase inhibitor for the potential 
treatment of inflammatory disorders including osteoarthritis. 
Introduction 
Blocking the cyclooxygenase (COX) pathway of arachidonic 
acid (AC) metabolism by conventional non-steroidal anti-
inflammatory drugs (NSAIDs) not only results in decreased 
production of gastroprotective prostaglandins (PGs) but also 
in the increased metabolism of AC via the 5-lipoxygenase (5-
LOX) route. This 'shunting effect' leads to increased 
production of leukotrienes (LTs), which contribute to 
inflammatory processes and further gastrointestinal (GI) 
damage. Thus, developing dual COX/5-LOX inhibitors may 
enhance anti-inflammatory effects and reduce the 
undesirable side effects associated with NSAIDs, especially 
those in the GI tract [472612]. 
 
Licofelone is the most promising of the dual COX/5-LOX 
inhibitors discovered by Merckle GmbH and is being 
developed by EuroAlliance (a consortium of Alfa 
Wassermann SpA, Lacer SA and Merckle). Pharmacological 
studies have demonstrated that the drug has analgesic, 
antipyretic, anti-inflammatory and significant anti-asthmatic 
activity without causing GI damage. It is currently in a 
phase III trial for the treatment of osteoarthritis (OA) 
[280077], [361142], [454683]. 
Synthesis and SAR 
Initial synthesis of licofelone proceeded with poor overall 
yield (< 5%) [159855]. Cossy and Belotti reported a short and 
efficient synthesis of licofelone that featured a thermal-acid-
promoted bicyclization of an ω-acetylenic amino ester 
[276312]. Basic phase-transfer catalysis of 1-chloro-3-phenyl-
2-propyne with isobutyraldehyde in the presence of NaI 
produced an aldehyde. This aldehyde was condensed with 
methyl glycinate hydrochloride under reductive amination 
conditions to yield an ω-acetylenic amino ester, which was 
heated at 150°C in the presence of 1 equivalent of pivalic 
acid to give tetrahydro-6-oxo-1H-pyrrolizine. Acylation with 
diethyl oxalate under basic conditions introduced a carboxylic 
Originator Merckle GmbH 
 
Licensees Alfa Wassermann SpA, Lacer SA 
 
Status Phase III Clinical 
 
Indications Inflammation, Osteoarthritis, Pain 
 
Actions 5-Lipoxygenase inhibitor, Analgesic, Cyclo-
oxygenase inhibitor, Non-steroidal anti-inflammatory 
 
Synonym ML-3000 
 
CAS 1H-Pyrrolizine-5-acetic acid, 6-(4-chlorophenyl)-2,3-
dihydro-2,2-dimethyl-7-phenyl- 
Registry No: 156897-06-2 
N
CH3
CH3
O
OHCl
 
 
acid side chain. The resulting β-diketone was entirely enolized. 
A Suzuki cross-coupling reaction was used to introduce the 
4-chlorophenyl group. Treatment with N-
phenyltrifluoromethanesulfonimide produced a triflate. This 
was coupled with (4-chlorophenyl)boronic acid in the 
presence of Pd(PPh3)4 and Na2CO3/H2O in refluxing 
tetrahydrofuran. The ethyl ester of licofelone was produced 
by deoxygenation via the 4-toluenesulfonylhydrazone, 
which after saponification led to licofelone at an overall 
yield of 19% [276312]. 
 
From a series of 6,7-diaryldihydropyrrolizin-5-yl acetic 
acids, licofelone, with its 4-chloro substituent, was the most 
potent and well-balanced dual inhibitor of both COX and  
5-LOX [159855]. 
Pharmacology 
The inhibition of COX and 5-LOX by licofelone was first 
determined in a bovine thrombocyte intact cell assay and 
intact bovine polymorphonuclear leukocytes, respectively 
(IC50 values of 0.21 µM for COX and 0.18 µM for 5-LOX) 
[159855]. In a human whole blood assay, licofelone (0.3, 1.0, 
3.0, 10 and 30 µg/ml) and indomethacin (0.3, 1.0, 3.0, 10  
and 30 µg/ml) concentration-dependently inhibited the 
synthesis of PGE2 (IC50 = 3.9 and 4.5 µM, respectively). In 
contrast to licofelone, indomethacin produced an increase in 
LTC4 of up to 155.5% of control. Furthermore, licofelone (1 to 
10 µM) inhibited the synthesis of LTB4 in a concentration-
related manner (IC50 = 3.6 µM) in a basophilic leukemia cell 
assay using RBL-1 cells [472600]. Licofelone inhibited LTC4 
formation by mixed polymorphonuclear leukocyte/platelet 
suspensions stimulated with A-23187 (IC50 = 3.8 µM). 
Licofelone also inhibited the generation of reactive oxygen 
species, release of elastase by polymorphonuclear 
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leukocytes, and homotypic polymorphonuclear leukocyte 
aggregation induced by N-formyl-methionyl-leucyl-phenyl-
alanine (fMLP), complement fraction 5a (C5A) and platelet 
activating factor (PAF), respectively [472601]. These in vitro 
studies demonstrated that licofelone inhibits 5-LOX as well 
as COX-1 and COX-2 activity, and therefore, polymorpho-
nuclear leukocyte responses relevant to the pathogenesis of 
inflammation. 
 
The pharmacodynamic profile of licofelone has been 
assessed and compared with widely used NSAIDs in 
various animal models. In a carrageenan-induced rat paw 
edema model, licofelone (10, 30 and 100 mg/kg) 
demonstrated an ED50 value of 17 mg/kg po and completely 
inhibited both PGE2 and LTB4 secretion, compared with 
indomethacin (10 mg/kg), which only inhibited secretion of 
PGE2 [472618]. 
 
In a rat adjuvant arthritis model, groups of rats (n = 10) were 
orally dosed with either licofelone (10, 25 or 50 mg/kg) or 
with indomethacin (1 mg/kg bid). Decreases in secondary 
lesions in rats treated with licofelone (25 mg/kg) were 
similar to the decreases observed with indomethacin, 
indicating that the anti-inflammatory activity of licofelone is 
comparable to indomethacin [472618]. 
 
An oral dose of licofelone (10 mg/kg) was more effective 
than an oral dose of aspirin (50 mg/kg) in a mouse phenyl-
quinone writhing model [472618]. The Randall and Selitto 
assay demonstrated that licofelone (30 mg/kg) was as 
effective as indomethacin (10 mg/kg) at increasing the pain 
threshold of inflamed paws in rats [472618]. 
 
In a brewer's yeast-induced hyperthermia model in rats, a 
significant antipyretic effect was noted with licofelone (10 
mg/kg po), which lasted 3 h and was comparable to the 
effect of indomethacin (10 mg/kg po) [472618]. 
 
Licofelone was highly effective and potent in a guinea pig 
model of AC-induced bronchoconstriction (ED50 = 0.2 mg/kg 
iv) [472618]. In addition, licofelone (100 mg), administered 
as an aerosol to allergic sheep before antigen challenge, 
significantly inhibited the early bronchial response and 
completely blocked late antigen-induced broncho-
constriction. It also attenuated airway hyper-responsiveness 
to aerosolized carbachol that occured 24 h after antigen 
challenge [326442]. 
 
In a rat laser-induced thrombus model, licofelone (10, 30 and 
100 mg/kg po) demonstrated significant antithrombotic 
activity comparable to aspirin (30 and 100 mg/kg po). An in 
vitro study demonstrated that licofelone (1 to 100 µg/ml) 
had a marked platelet aggregation inhibiting effect [472602]. 
 
In a rat adjuvant arthritis model, licofelone (20 or 80 
mg/kg/day bid for 28 days) significantly reduced the 
arthritis-associated deficiency of body growth, the 
edema/erythema score and splenomegaly. In the ankle joint, 
licofelone significantly reduced the overall histological 
score, synovial cell proliferation and bone/cartilage 
erosions, and also inhibited the appearance of 
fibroproliferative pannus [472610]. In the anterior cruciate 
ligament transection OA dog model, licofelone (2.5 and 5 
mg/kg/day for 8 weeks) significantly decreased the size, 
grade and severity of cartilage lesions in the condyles and 
plateaus. It significantly decreased the level of PGE2 in 
synovial fluid and LTB4 production by synovium. Licofelone 
also markedly reduced the levels of collagenase 1 in 
cartilage and IL-1β in the synovial membrane [472608]. In 
another study using this model, licofelone (2.5 and 5 
mg/kg/day for 8 weeks) markedly reduced the level of 
chondrocyte apoptosis, and significantly decreased the 
levels of caspase-3, COX-2 and iNOS in cartilage from both 
condyles and plateaus [472595]. In vitro, licofelone (0.8 to 8 
µM) inhibited the production of PGE2 and LTB4 by OA 
osteoblasts at the highest dose, dose-dependently stimulated 
1,25-dihydroxy vitamin D-induced alkaline phosphatase 
activity, and inhibited osteocalcin release via its effect on 
LTB4 production [472594]. These results suggest that 
licofelone could be used as a disease-modifying drug for the 
treatment of OA and rheumatoid arthritis (RA). 
 
The gastric-sparing properties of licofelone have also been 
investigated. The drug dose-dependently inhibited ATPase 
activity in pig gastric microsomes with an IC50 value of 16.6 
µM. When the drug was diluted by 100-fold, the inhibitory 
effect was abolished. Licofelone-treated human gastric 
adenocarcinoma cells secreted less baseline and IL-1β-
induced IL-8 with IC50 values of 0.82 and 1.2 µM, 
respectively [490628]. 
Metabolism 
Plasma levels and distribution of radioactivity were 
examined using whole-body autoradiography after oral 
administration of 14C-labeled licofelone (13.7 to 26.6 mg/kg) 
to female rats. Plasma levels of licofelone peaked at 3 to 4 h 
after administration, with a plasma t1/2 of ~ 11 h. The highest 
tissue levels of licofelone were detected in the lung, liver, 
kidney, heart and intestine. Almost no penetration of the 
blood-brain barrier was noted; however, after 48 h there was 
a minor accumulation in fat. Of the total radioactivity, 58.3% 
was found in the feces and 7.9% in the urine [215072]. 
 
Licofelone (200 mg bid for 5 days and a single final dose of 
200 mg on day 6) was administered in 18 healthy male and 
female young (mean age of 30.9 years) and elderly (mean 
age of 72.1 years) individuals. Following the first dose, mean 
Cmax was similar for young (1665 ± 1151 ng/ml) and elderly 
(1637 ± 903 ng/ml) individuals. The maximum plasma 
concentrations were reached 0.74 to 4 h after administration, 
while the mean AUC(0 to 12) was 23% lower in the young 
individuals (5646 ± 2073 versus 4582 ± 1927 ng.h/ml). 
Licofelone demonstrated similar Cmax values in the two 
groups at steady-state, with young individuals having a Cmax 
value of 1727 ± 829 ng/ml and elderly individuals having a 
Cmax value of 1744 ± 616 ng/ml; the AUC was 20% higher in 
elderly individuals. t1/2(β) was greater in young individuals 
than elderly ones (11.1 ± 7.0 versus 8.7 ± 4.7 h), while the 
mean t1/2(α) value was 15% higher in the elderly study 
population [477522]. No pharmacokinetic interaction 
between licofelone and warfarin was observed, suggesting 
that the two drugs have different elimination pathways 
[477523]. 
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Toxicity 
GI side effects of licofelone versus indomethacin and 
diclofenac were examined in a rat and rabbit model, 
respectively [171427], [198442]. A single oral administration 
of licofelone (10 to 100 mg/kg) produced no acute GI 
damage in rats. Repeated oral administration of licofelone at 
the same doses produced slight, but not significant, GI 
damage after 5 days, although duodenal ulcers did appear 
in some rats at doses of 30 and 100 mg/kg, after 11 days. In 
rabbits, repeated oral administration of licofelone over 4 
days did not produce any detectable GI damage at doses of 
10 or 30 mg/kg, but an ulcer was observed in one of five 
rabbits given the 100-mg/kg dose. GI damage from 
indomethacin (0.3, 1.0 or 3.0 mg/kg) or diclofenac (1.0 or 3.0 
mg/kg), however, was more severe and occurred even after 
a single administration at low doses. The favorable GI 
tolerability of licofelone is believed to be linked to the 
mechanism of combined 5-LOX and COX inhibition; LTB4 
levels in the rat stomach were higher in indomethacin- (0.3, 
1.0 or 3.0 mg/kg) or diclofenac- (1.0 or 3.0 mg/kg) treated 
animals (LTB4 increased by up to 9.2 or 8.9 pg/mg protein 
over control) than licofelone (10, 30 or 100 mg/kg), which 
was comparable to control (2.5 pg/mg protein) [472600]. 
 
General pharmacological studies demonstrated that oral 
administration of licofelone (30, 100 or 300 mg/kg) did not 
affect the central nervous system. Licofelone (100 mg/kg id) 
had no notable effect on the cardiovascular system, 
respiration or neuromuscular function in experimental 
animals. A small transient reduction in urine volume was 
observed after the highest dose, accompanied by decreases 
in electrolyte excretion at doses of 100 and 300 mg/kg in rats 
[198441]. Further study demonstrated that licofelone had no 
genotoxic potential in bacteria and mammalian cells in vitro 
[183587]. 
Clinical Development 
Phase I 
Licofelone (200 mg bid for 5 days and a final dose of 200 mg 
in the morning of day 6) was well tolerated in 18 young and 
elderly healthy individuals [477522]. GI tolerability of 
licofelone was studied with endoscopic evaluation of gastric 
and duodenal mucosa in healthy volunteers. Healthy 
individuals (n = 121, mean age of 42 years) with normal 
gastric and duodenal mucosa were treated for 4 weeks with 
licofelone (200 or 400 mg bid), placebo or naproxen (500 mg 
bid). Before and after treatment, the mucosa was evaluated 
with modified Lanza scores (a standard rating scale of the 
integrity of the GI mucosa) and ulcers were assessed (3 mm 
or more in diameter). After 4 weeks, the gastric mucosa was 
normal in 93% of subjects following treatment with 200 mg 
bid of licofelone, 89% of those who took 400 mg bid, 90% of 
those treated with placebo and in 37% of those who took 
naproxen. No ulcers were present in either the licofelone 
group or the placebo group; however, six ulcers (20%) were 
observed in the naproxen group [328497], [385041], [477524]. 
Phase II 
Two double-blind, randomized, placebo-controlled, phase II 
studies carried out to test the efficacy of licofelone 
demonstrated a clear dose-response relationship in patients 
with radiographically and clinically confirmed OA of the 
knee. In the first study, 107 patients were randomized to 
receive licofelone (100, 200 or 400 mg bid) or placebo for 4 
weeks. Doses of 200 and 400 mg bid were effective at 
relieving symptoms such as pain and stiffness, as 
determined using the WOMAC index as a global score, and 
pain, stiffness and disability as subscores. These scores were 
highly significant compared with placebo. The second study 
treated 404 patients with licofelone (100, 200 or 400 mg bid), 
diclofenac (50 mg tid) or placebo for 4 weeks. All three doses 
of licofelone produced superior effects compared with 
placebo, with mean percentage decreases in the WOMAC 
pain subscore of 37 (p < 0.025), 40 (p < 0.018) and 42%  
(p < 0.005) for the 100-, 200- and 400-mg doses, respectively. 
Improvements in secondary endpoints (pain, stiffness and 
disability) were also greater in the licofelone groups than in 
the placebo group. No significant difference was noted 
between the licofelone and diclofenac groups. In both 
studies, treatment with licofelone was well tolerated across 
the dose range. Patients in the 100- and 200-mg groups 
experienced fewer adverse events, including fewer GI 
events, than the 400-mg group, and a comparable number to 
placebo treatment. The most common adverse events were 
diarrhea and abdominal pain [385041], [388969]. 
Phase III 
Patients (n = 148) with OA were administered either 
licofelone (200 mg bid) or naproxen (500 mg bid) for 12 
weeks. A response was defined as a 30% improvement over 
baseline on the WOMAC index. Efficacy was similar in the 
two groups, with 69% responding in the licofelone group  
(n = 72) and 68% in the naproxen group (n = 76). Only 14% 
of licofelone-treated patients, however, reported GI side 
effects and 1.5% developed gastroduodenal ulcers, 
compared with 26 and 15%, respectively, of those on 
naproxen. The most common adverse events were 
abdominal pain/discomfort, which were evident in 4.2% of 
patients on licofelone compared with 7.9% of those on 
naproxen (p = 0.03) [477524], [477531]. 
 
The long-term safety and efficacy of licofelone (100 or 200 
mg bid) was compared with naproxen (500 mg bid) in a 52-
week, double-blind study in 710 patients with OA of the 
knee. Both doses of licofelone demonstrated a similar 
efficacy to naproxen at week 4, while the efficacy of 
licofelone improved throughout the 52 weeks of the study. 
The general and GI tolerability of licofelone were better than 
naproxen. Licofelone had a lower incidence of hypertension 
aggravation than naproxen (0.4% in both doses of licofelone 
versus 3.1% in naproxen, p = 0.017). The total incidence of GI 
ulcers in phase III studies was 0.14% for the 100-mg bid dose 
of licofelone, 0.39% for the 200-mg bid dose and 2.5% for 
naproxen [477531]. 
 
The incidence of endoscopically diagnosed ulcers in OA 
patients has been measured in two studies, one in which all 
patients took low-dose aspirin and the other in which they 
did not. Patients were then randomized to receive either 
licofelone (400 mg bid) or naproxen (500 mg bid). In the low-
dose aspirin group, incidence of gastroduodenal ulcers 
during the first 6 weeks was 25.6 and 5.6% in naproxen- and 
licofelone-treated patients, while the incidence of gastric 
ulcers was 23 and 2.4%, respectively. Licofelone-treated 
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patients in both studies had ulcer incident rates similar to 
placebo-treated patients in comparable published studies 
without low-dose aspirin [477532].  
Side Effects and Contraindications 
Licofelone has fewer general and GI side effects compared 
with conventional NSAIDs. The most common adverse 
effects were diarrhea and abdominal pain. No increased 
ulceration was evident when licofelone was co-administered 
with aspirin [477532]. 
Current Opinion 
Clinical studies have demonstrated that licofelone is 
effective in the treatment of OA and is comparable to the 
conventional NSAIDs naproxen and diclofenac. Licofelone is 
well tolerated and has fewer side effects than naproxen and 
diclofenac. These results suggest that dual inhibition of  
COX and 5-LOX may reduce the undesirable GI side effects  
associated with NSAIDs. Although it has been suggested 
that the rate of adverse events associated with licofelone 
may be comparable to selective COX-2 inhibitors with the 
possibility of less risk of cardiovascular and thromboembolic 
complications [477531], there is no direct clinical evidence to 
support this and further trials are needed to test it. In 
addition, based on pharmacological studies, it has been 
suggested that licofelone may be a disease-modifying drug; 
however, this will need to be determined in well-designed 
trials [468870]. If these claims are proven, licofelone will 
become a credible alternative to conventional NSAIDs and 
selective COX-2 inhibitors in the treatment of OA and 
capture a substantial proportion of the considerable market 
for OA therapies. Like conventional NSAIDs, dual COX and 
5-LOX inhibitors may also decrease the production of 
physiological 'housekeeping' PGs, and thus induce potential 
side effects. The renal side effects of licofelone that occurred 
in general pharmacological studies should be a matter of 
concern in further clinical studies [198441]. 
 
Licensing 
Alfa Wassermann SpA/Laboratoire L Lafon SA/Lacer SA 
By December 1995, licofelone was being developed by EuroAlliance, a consortium of Alfa Wassermann SpA, Laboratoire L 
Lafon SA, Lacer SA and the originator Merckle GmbH. However, Lafon left the agreement in 1996 to 'pursue different 
strategies' [194999], [227131]. 
Forest Laboratories Inc 
In April 2000, Forest Laboratories Inc licensed the drug from Merckle for development and marketing in the US. No financial 
details were disclosed. In March 2002, Forest terminated its agreement with Merckle for licofelone, commenting that the 
likelihood of successfully completing the three pivotal studies required for US approval did not justify the company's 
continued investment [362605], [443377]. However, in April 2002, Merckle reached an agreement with Forest which would 
allow the continuation of ongoing clinical trials to develop licofelone for the US market. Both parties agreed that Forest 
would continue managing the ongoing US placebo-controlled efficacy study for licofelone for a reasonable period until 
Merckle was in a position to take over full legal and logistical responsibility for completion of the study, although Forest 
would no longer be involved in the development of the drug [447895]. 
Development history 
Licofelone entered phase III trials in March 2000 for the potential treatment of OA in Germany, Belgium, the Netherlands, 
Spain, the Czech Republic and Poland [361142]. In 1995, licofelone was also in phase II trials for the treatment of RA and 
associated pain [194999]. In February 1998, Merckle announced that completion of phase II pilot studies in RA patients was 
due by March 1998, at which point it hoped to extend phase II trials in the two main indications, RA and OA [280077]. 
However, no development for RA has been reported since that time. 
 
Developer Country Status Indication Date Reference 
Alfa Wassermann SpA Italy Phase III Osteoarthritis 03-APR-00 361142 
 
Lacer SA Spain Phase III Osteoarthritis 03-APR-00 361142 
 
Merckle GmbH Germany Phase III Osteoarthritis 03-APR-00 361142 
 
Alfa Wassermann SpA Italy Phase II Inflammation 01-JUL-97 250972 
 
Alfa Wassermann SpA Italy Phase II Pain 01-JUL-97 250972 
 
Lacer SA Spain Phase II Inflammation 01-JUL-97 250972 
 
Lacer SA Spain Phase II Pain 01-JUL-97 250972 
 
Merckle GmbH Germany Phase II Inflammation 01-JUL-97 250972 
 
Merckle GmbH Germany Phase II Pain 01-JUL-97 250972 
 
Alfa Wassermann SpA Italy No development reported Rheumatoid arthritis 04-MAR-03       - 
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Development history (continued) 
Developer Country Status Indication Date Reference 
Lacer SA Spain No development reported  Rheumatoid arthritis 04-MAR-03        - 
 
Merckle GmbH Germany  No development reported Rheumatoid arthritis 04-MAR-03 
 
       - 
Forest Laboratories Inc US Discontinued Osteoarthritis 14-MAR-02 443377 
 
Laboratoire L Lafon SA  France Discontinued Inflammation 01-NOV-96 227131 
 
Laboratoire L Lafon SA  France Discontinued Pain 01-NOV-96 227131 
 
Literature classifications 
Key references relating to the drug are classified according to a set of standard heading to provide a quick guide to the 
bibliography. These headings are as follows: 
Chemistry: References which discuss synthesis and structure-activity relationships. 
Biology: References which disclose aspects of the drug's pharmacology in animal models. 
Metabolism: References that discuss metabolism, pharmacokinetics and toxicity. 
Clinical: Reports of clinical phase studies in volunteers providing, where available, data on the following: Whether the 
experiment is placebo-controlled or double- or single-blind; number of patients; dosage. 
Chemistry 
Study type  Results Reference 
Synthesis. Licofelone was synthesized from 1-chloro-3-phenyl-2-propyne in an overall yield of 19%. The method 
features the use of a thermally induced bicyclization of an ω-acetylenic amino ester. 
276312 
 
 
SAR. Licofelone, containing a 4-chloro substituent, was the most potent and well-balanced dual inhibitor of 
COX and 5-LOX. 
 
159855 
Biology 
Study Type Effect Studied Experimental Model Result Reference 
In vivo Anti-inflammatory. Carrageenan-induced 
rat paw edema. 
Licofelone had an ED50 value of 17 mg/kg po and 
completely inhibited both PGE2 and LTB4 secretion at a 
single dose (10, 30 or 100 mg/kg). Indomethacin  
(10 mg/kg) only inhibited PGE2. 
 
472618 
In vivo Anti-inflammatory. Rat adjuvant arthritis. Decreases in secondary lesions of rats treated with 
licofelone (25 mg/kg) were similar to the decreases 
noted with indomethacin (1 mg/kg bid). 
 
472618 
In vivo Analgesic. Mouse phenyl-quinone 
writhing model. 
 
Licofelone (30 mg/kg) was more effective than aspirin 
(50 mg/kg).  
472618 
In vivo Antipyretic. Brewer's yeast-induced 
hyperthermia model in 
rats. 
A significant antipyretic effect was noted with licofelone 
(10 mg/kg po) that lasted for 3 h; this was comparable 
to the effect of indomethacin (10 mg/kg po). 
 
472618 
In vivo Anti-asthmatic. AC-induced 
bronchoconstriction in 
guinea pigs. 
 
Licofelone was highly effective and potent  
(ED50 = 0.2 mg/kg iv). 
472618 
In vivo Antithrombotic. Laser-induced 
thrombus in rats. 
Licofelone (10, 30 and 100 mg/kg po) demonstrated 
significant antithrombotic activity, comparable with that 
of aspirin (30 and 100 mg/kg po). 
 
472602 
In vivo Disease-modifying. Osteoarthritic dogs. Licofelone (2.5 and 5 mg/kg/day for 8 weeks) 
significantly decreased the size, grade and severity of 
cartilage lesions in condyles and plateaus, decreased 
the level of PGE2 in synovial fluid and LTB4 production 
by synovium, and reduced the levels of collagenase 1 in 
cartilage and IL-1β in synovial membrane. 
 
472608 
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Metabolism 
Study Type Effect Studied Model Used Result Reference 
In vivo Pharmacokinetics. Healthy male and 
female, young (mean 
age of 30.9 years) and 
elderly (mean age of 
72.1 years) volunteers. 
Maximal plasma concentrations were achieved 0.74 to 
4 h after dose administration. The rates of systemic 
elimination were 11.1 ± 7.0 h in young individuals and 
8.7 ± 4.7 h in elderly individuals. The mean t1/2 (α) value 
was 15% higher in the elderly population. 
 
477522 
Clinical 
Effect Studied Model Used Result Reference 
Safety and 
tolerability. 
Phase I trial in healthy 
volunteers (n = 121) with 
normal gastric and 
duodenal mucosa. 
 
After 4 weeks, the gastric mucosa was completely normal in 93% of 
volunteers given licofelone (200 mg bid), 89% given licofelone (400 mg 
bid), 90% given placebo and 37% given naproxen (500 mg bid).  
 
477524 
Efficacy and 
safety. 
Phase II trial in OA 
patients (n = 107). 
Doses of 100, 200 or 400 mg bid of licofelone for 4 weeks demonstrated 
a significant, superior effect compared with placebo, and a similar effect 
to diclofenac (50 mg tid). Treatment with licofelone was well tolerated. 
 
385041 
388969 
Efficacy and 
safety. 
Phase III trial in OA 
patients (n = 148). 
Efficacy was similar for patients given 200 mg of licofelone bid or 500 mg 
bid naproxen for 12 weeks. Only 14% of licofelone-treated patients 
reported GI side effects compared with 26% of those treated with 
naproxen. 
 
477524 
Safety and 
efficacy. 
Phase III trial in patients 
(n = 710) with OA of the 
knee. 
Doses of 100 or 200 mg bid licofelone demonstrated similar efficacy to 
naproxen 500 mg bid from week 4. The general tolerability and the GI 
tolerability of licofelone were better than naproxen. 
 
477531 
 
Associated patent 
 
Title Substituted pyrrole compounds and their use as pharmaceuticals. 
 
Assignee Dannhardt G 
 
Publication EP-00397175 14-NOV-90 
 
Priority DE-03915450 11-MAY-89 
 
Inventors Dannhardt G, Steindl L, Lehr M, Laufer S. 
Associated references 
 
•  of special interest 
 
159855 (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of 
potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. 
Laufer SA, Augustin J, Dannhardt G, Kiefer W J MED CHEM 1994 37 12 
1894-1897 
 
171427 ML-3000 reduces gastric prostaglandin synthesis without 
causing mucosal injury. Wallace JL, Carter L, McKnight W, Tries S, Laufer 
S EUR J PHARMACOL 1994 271 2-3 525-531 
• Evaluation of the effects of licofelone on the gastric mucosa, including 
determination of gastric prostaglandin levels and comparison to diclofenac in 
terms of ulcerogenic potential in a rabbit model of penetrating, chronic antral 
ulceration. 
 
183587 Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-
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